Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Why Algernon is investigating DMT in stroke rehabilitation

By Brian Buntz | September 29, 2022

AlgernonThe clinical-stage company Algernon Pharmaceuticals (CSE:AGN; Frankfurt:AGW0; OTCQB: AGNPF) has received approval to run a Phase 1 clinical study of an IV formulation of AP-188.

The study will explore the drug candidate’s potential, a formulation of the classic psychedelic N,N-dimethyl tryptamine or DMT, to treat stroke patients in the Netherlands.

The Stichting Beoordeling Ethiek Biomedisch Onderzoek (“BEBO”), an independent medical research ethics committee, will manage the study.

Algernon decided to investigate the potential of DMT in human studies for ischemic stroke after reviewing data from independent studies demonstrating that DMT can mitigate tissue damage while promoting neurogenesis and neuroplasticity.

To learn more about Algernon’s plans to explore the potential of DMT as a therapy for ischemic stroke, we spoke with Christopher J. Moreau, the company’s CEO.

What led to your interest in DMT as a potential treatment for ischemic stroke?

Chris-Moreau

Christopher Moreau

Moreau: There was significant capital markets interest in psychedelic drugs research in the fall of 2020, and one of our lead investors asked me to look and see if there was a research program we could develop. I told him unless it was a pure “pharma business play,” we would not be interested in advancing any research.

Significant preclinical evidence, both in vitro and in vivo, shows that the psychedelic drug DMT promotes neuroplasticity. For example, in a preclinical research study conducted at UC Davis, cortical rat neurons showed increased neuroplasticity when exposed to amphetamine, LSD and DMT, showing a class effect. DMT is of particular interest as a therapeutic agent because it has a half-life of only 8 minutes in the body.

In a stroke animal study conducted by Nardai in Hungary, rats that were given DMT after the stroke injury occurred showed a significant reduction in the infarct volume from the stroke and had almost a full recovery of their motor function measured over time.

Helping the brain heal after a stroke injury represents a new model and approach for stroke treatment and may be one of the most promising since the approval of tissue plasminogen activator (TPA) in 1996.

In an independent preclinical study, Algernon further confirmed that a sub-psychedelic or microdose of DMT also caused neuronal outgrowth. As a result, Algernon will investigate a sub-psychedelic dose in patients in a Phase 1 DMT stroke study planned to begin in Q4, 2022.

Algernon has synthesized a supply of cGMP DMT, filed composition of matter patents for new salt formulations of DMT, dosing and combination treatment patents, and is about to begin a Phase 1 clinical trial for stroke, all key elements of a “pure pharma play.”

Could you provide a brief overview of your pipeline and how DMT plugs into that?

Moreau: Algernon’s drug discovery approach has been based on drug repurposing, finding new uses for drugs that are off patent, have a known safety history and, based on their target and mechanism of action, can treat indications other than their original use. Algernon only investigates drugs that have never been approved in the United States or Europe.

Algernon is advancing Ifenprodil for idiopathic primary fibrosis and chronic cough. Ifenprodil is an ex-Sanofi drug sold only in Japan and South Korea to treat vertigo.

Algernon is also advancing an ex-Mitsubishi drug called repirinast, originally used to treat Asthma, for chronic kidney disease.

DMT, while never approved, has been used for centuries for its psychedelic effects. Algernon is repositioning it for the treatment of stroke.

How did Algernon partner with researchers at the Centre for Human Drug Research in the Netherlands?

Algernon originally applied to conduct its DMT study in the UK in early 2021, working with an organization called Hammersmith Medical Research. The company was planning to deliver an intravenous formulation of DMT which was going to be developed at the Hammersmith laboratory. It turned out that the facility couldn’t meet all of the requirements asked of us by the Medicines and Healthcare Products Regulatory Agency (WHRA) in the UK.

We began to look for another vendor and discovered that Ethan Biomedical had run a Phase 1 DMT study for depression at the Center for Human Drug Research (CHDR) in the Netherlands. So we made contact and went from there. CHDR was able to deliver a cGMP DMT finished intravenous product formulation as well as conduct our clinical Phase 1 study on-site. As a result, we applied for ethics and clinical trial approval from the Netherlands regulatory authority, which we received on September 12, 2022.

Could you share more on how Algernon tapped DMT research pioneer Rick Strassman MD and the psychedelic researcher Dr. David Nutt, as consultants?

Moreau: The process was very simple, basic and without fanfare. We were able to identify their personal contact information. When we reached out to them, we sent them the preclinical data we had aggregated on DMT and its potential as a stroke treatment and our preclinical and clinical plan for the drug. It wasn’t long after that they both responded, and after hearing our story and no doubt doing some research on Algernon the company, they decided that they would be willing to help us with our research program by joining our advisory board. Both of them have been extremely helpful with their input and guidance of our clinical research and regulatory teams as we advance our DMT research program forward.


Filed Under: Cardiovascular, Neurological Disease, Psychiatric/psychotropic drugs
Tagged With: Algernon, Algernon Pharmaceuticals
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Human study tracks brain’s glymphatic flow in real time, opening Alzheimer’s drug avenues
An 8-year-old patient with gangliosidosis demonstrates improved mobility, walking unassisted on a soccer field after treatment with N-acetyl-L-leucine. (Still from video footage; parental consent obtained for use).
Modified amino acid approved for Niemann–Pick shows promise in early Parkinson’s research
AI-guided hunt points to PHGDH as an upstream drug target in Alzheimer’s disease
Why smaller, simpler molecular glues are gaining attention in drug discovery
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE